

Claims

1. A pharmaceutical composition adapted to control spermatogenesis, comprising:
 - (a) for positive control
one or more substances of
CREM, a CREM-phosphorylating compound and a CREM expression inducing compound, and/or
 - (b) for negative control
one or more substances of
a CREM-inhibiting compound, a CREM phosphorylation inhibiting compound, and a CREM expression inhibiting compound.
2. The pharmaceutical composition according to claim 1, characterized in that the CREM-phosphorylating compound is a kinase, and the CREM phosphorylation inhibiting compound is a kinase inhibitor.
3. A process for investigating spermatogenesis and monitoring it, respectively, wherein CREM and/or CREM-dependent proteins are determined.
4. The process according to claim 3, characterized in that the CREM-dependent proteins are proacrosin, protamine, Tp-1, MCS and/or RT7.
5. A kit for carrying out the process according to claim 3 or 4, comprising one or more of (a) to (c)
 - (a) primers for amplifying DNA coding for CREM and/or CREM-dependent proteins,
 - (b) antibodies against CREM and/or CREM-dependent proteins,

- (c) DNA samples for mRNA of CREM and/or CREM-dependent proteins, as well as
 - (d) standards and detection reagents for one or more of (a) to (c), and
 - (e) carriers as well as conventional vehicles.
6. A kit according to claim 5, characterized in that the CREM-dependent proteins are proacrosin, protamine, Tp-1, MCS and/or RT7.
7. Use of (b) of the pharmaceutical composition according to claim 1 or 2 for controlling the fertility in male persons.

Amended Claims

1. A process for investigating spermatogenesis and monitoring it, respectively, wherein CREM and/or CREM-dependent proteins are determined.
2. The process according to claim 1, characterized in that the CREM-dependent proteins are proacrosin, protamine, Tp-1, MCS and/or RT7.
3. A kit for carrying out the process according to claim 1 or 2, comprising one or more of (a) to (c)
A
 - (a) primers for amplifying DNA coding for CREM and/or CREM-dependent proteins,
 - (b) antibodies against CREM and/or CREM-dependent proteins,
 - (c) DNA samples for mRNA of CREM and/or CREM-dependent proteins, as well as
 - (d) standards and detection reagents for one or more of (a) to (c), and
 - (e) carriers as well as conventional vehicles.
4. A kit according to claim 5, characterized in that the CREM-dependent proteins are proacrosin, protamine, Tp-1, MCS and/or RT7.

add
B